Lv51
1090 积分 2021-11-04 加入
The Lancet Breast Cancer Commission
1天前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
18天前
已完结
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
1个月前
已完结
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
1个月前
已完结
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer
1个月前
已完结
Giredestrant for Estrogen Receptor-Positive, HER2 Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Studyy
9个月前
已关闭
A Phase 1 dose escalation and expansion trial of the next-generationoral SERD camizestrant in women with ER-positive, HER2-negativeadvanced breast cancer: SERENA-1 monotherapy results
9个月前
已完结
Camizestrant, a next-generation oral SERD, versus fulvestrant in post.menopausal women with oestrogen receptor-positive, HER2-negative advancedbreast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
9个月前
已完结
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
9个月前
已完结
皖公网安备34019202002308
